China Approves First AI-Designed Drug for COVID-19 Treatment
- Published:
- First detected:
Insights by Echo AI
China's National Medical Products Administration (NMPA) has approved an innovative class 1 drug, Mprosevir, developed using artificial intelligence for the first time. The drug is intended for treating mild to moderate COVID-19 in adults. The development process, from finding a promising compound to successful clinical trials, took just 3.5 years, significantly faster than the traditional 10 to 15 years. AI played a key role in selecting effective compounds from a database of 49 billion molecular compounds and optimizing the molecule's properties.
Source coverage
12
records merged
0
0 unique
11
11 unique
1
1 unique
12 Sources
Лекарство, созданное при участии ИИ, впервые одобрили в Китае. На рын...
😷 В Китае впервые одобрили лекарство, созданное при участии ИИ В Кита...
Китай одобрил первое созданное с помощью ИИ лекарство Национальное упр...
Unlock Echo Intelligence
Move beyond the public feed. Monitor breaking stories across Telegram, X, and the web — with earlier visibility, clearer context, and complete control over your sources.
- Monitor Telegram, X, and web in one place
- Add any source, from niche channels to global outlets
- Build custom feeds around events, regions, entities, or keywords
- Merge duplicate coverage into one clear, source-transparent story
- Auto-translate summaries and full articles
- Search past coverage and use AI-powered editorial tools
